Individual investor with particular interest in any company that is on the cusp of change--for the better. These companies will have at least several attributes in common: They are underfollowed; underappreciated; have a clear, stated strategy for driving profits; management and BOD are perfectly aligned with common shareholders; management team and BOD with a track record of rewarding shareholders; and have near-term catalysts that will have meaningful impact on the business. Simple, right?
I have a Bachelors Degree In Business Administration. I have been investing in biotech stocks for many years, and I prefer to invest as a long term investor. With that In mind I seek stocks that have long term value! I primarily Like to Invest In biotechnology stocks and I accept the risks.
I Write for the Healthcare Sector and Stock market in general. I contribute to Seeking Alpha, Talk Markets, and CNA Finance. I run my own biotechnology website Biotechpicklist.com and in addition I post stock market news on my other website Wallstreetrain.com
For over ten years Mr. Bach, as General Counsel, has provided Whitmore with his expertise on all corporate legal issues and has shepherded its growth through his counsel and guidance as the company’s Executive Vice-President of Mergers and Acquisitions. In 2005, Mr. Bach formed Whitmore & Co., a commercial real estate brokerage, to service the commercial real estate insurance client of the company. Whitmore & Co. provides clients of Whitmore with the opportunity to source and market commercial real estate to other Whitmore clients, giving them personalized services tailored to their needs and to purchase or dispose of their real estate to an elite, pre-qualified group, of users, investors and developers.
Prior to joining Whitmore, Mr. Bach had been President/CEO and Chairman of the Board of T SI Environmental, Inc. (TSIN-NASDAQ: Bulletin Board), Saltville, Virginia. Joining TSI as Chief Operating Officer and General Counsel, Mr. Bach oversaw all aspects of the management and marketing functions of the company, and increased revenue threefold during his tenure.
Before his affiliation with TSI, Mr. Bach had been a principal, officer and director of several privately held companies, including President of Atlantic Coast Construction Co. of New York and Vice-President and General Counsel to Hugh P. Gaffney Co., Inc., a real estate development and brokerage firm, and Morgan Gentry’s Inc, a restaurant development and operating company. In these various positions, Mr. Bach's responsibilities included negotiations, acquisitions, and development of residential and commercial properties, with complete oversight, including negotiation of contracts, implementation of development plans, and review of all zoning and governmental regulations; and restaurant design, oversight, supervision, and operation.
Mr. Bach's professional career began as Legislative Counsel to Hon. John R. Dunne, New York State Senate and as Minority Counsel to the New York State Temporary Commission on Management and Productivity in the Public Sector.
Subsequently, Mr. Bach joined the firm of Sprague, Dwyer, Aspland and Tobin, P.C. in Garden City, New York and specialized in Banking, Real Estate and Commercial Transactions, which involved him in the negotiation and drafting of real estate contracts and commercial transactions; counseling of financial institutions (commercial bank and savings and loan association) regarding regulations and transactions; and zoning matters. Mr. Bach has also been engaged in private practice for thirty years specializing in real estate transactions, development, and zoning matters.
Mr. Bach received his Bachelor of Arts Degree in English Literature from St. John's University, St. John's College, Jamaica, New York as well as his Doctor of Jurisprudence from St. John's University, School of Law. He attended the Masters of Law Program at New York University, School of Law, New York, New York.
Brian Gilmartin, is a portfolio manager at Trinity Asset Management, a firm he founded in May, 1995, catering to individual investors and institutions that werent getting the attention and service deserved, from larger firms. Brian started in the business as a fixed-income / credit analyst, with a Chicago broker-dealer, and then worked at Stein Roe & Farnham in Chicago, from 1992 - 1995, before striking out on his own and managing equity and balanced accounts for clients. Brian has a BSBA (Finance) from Xavier University, Cincinnati, Ohio, (1982) and an MBA (Finance) from Loyola University, Chicago, January, 1985. The CFA was awarded in 1994. Brian has been fortunate enough to write for the TheStreet.com from 2000 to 2012, and then the WallStreet AllStars from August 2011, to Spring, 2012. Brian also wrote for Minyanville.com, and has been quoted in numerous publications including the Wall Street Journal.
Individual investor, part-time, about 20 hours a week. Medical and research background has been helpful in my area of interest which is highly speculative biotechs - device, drugs, and drug delivery platforms.
Over 30 years of investing in individual stocks. Extensive business experience with small to mid-size companies, including as CEO. Many hundreds of blog posts on financial and economic matters since 2008. Focus on value with catalysts for upside price action. Background as a physician and pharmaceutical inventor and entrepreneur, however focus now is global and involves almost all economic categories.
I have a B.S. in Chemical Engineering from the University of Maryland and have worked on FDA clinical trials in the medical device industry for the last 10 years. I have more than 25 years investing experience.
Individual investor - with background in pharma, intellectual property, legal, regulatory, business and related strategic initiatives. President of PersisPharma LLC, since October 2014. PersisPharma is engaged in exploratory pharmaceutical research and related product development.
The Life Sciences Report features leading investment coverage of the life sciences sector, including biotechnology, pharmaceuticals, tools & diagnostics, and medical devices. A Streetwise Reports publication. www.TheLifeSciencesReport.com
Sirius capital is a Life Science consultancy firm providing guidance to investors and entrepreneurs in private and publicly traded companies. The managers are Mr. Dror Ozeri, CPA. Adv. and Dr. Ariel Kamsler PhD who combine their extensive experience in Pharma and drug development with financial management expertise.
I worked almost 30 years in the pharmaceutical industry. I started as a sales rep after earning my degree in biological sciences and (later) biomedical sciences. I then went back to school, got my MBA, and spent the following 20 years working up the ranks. I spent the latter parts of my career working as an analyst, meaning I would analyze data on 1,000s of compounds, collect reports from scientists, and then present the information to those who decided whether the candidates would go on to clinical trials (additional preclinical studies) or would be thrown to the dumpster for some small company to find and develop further. I have worked in just about every department in the pharmaceutical industry, including biotechnology, oncology, infectious disease, genetics, etc.
Now that I am recently retired, I have joined Seeking Alpha to share my knowledge of the healthcare industry, and discuss trends that I've seen throughout my career. I have chosen the task of managing my own retirement accounts, therefore Seeking Alpha has become a great interest to me.
I am hoping to learn and teach via Seeking Alpha. Also, my grandchildren call me Shennie so that's what I go by these days
Allan Harris is an outspoken advocate for technical analysis via pattern recognition as the only effective methodology for making money trading the stock market. Allan has been involved in the markets for 40 years, starting as an options trader while attending law school in the late 1970's and ultimately becoming a professional trader after retiring from the practice of law in 1994. A prolific contributor to various stock market forums, including the Gilder Technology Forum in the 1990's, he started his own free stock market blog in 2004 that later evolved into AllanTrends.com, a subscription based trading service based upon a proprietary trend identification algorithm. Using a novel staggered profit taking strategy his service trades intermediate and short term trends in a basket of stocks and ETF's with outstanding trending characteristics.
Stephen Simpson, CFA, is a freelance financial writer and investor.
I have worked for both sell-side and buy-side firms (equities and fixed income), with the largest percentage of my working time spent in med-tech. At this point I am now effectively in a "working retirement".
I write because I find that the process helps me take better notes, be more disciplined about modeling, and come up with a more coherent investment view for my portfolio management needs. If I'm writing about a stock, it's generally because I'm interested in it as an investment prospect or I think there's an interesting story to tell.
I don't share my models, so please don't ask.
More of my writings can be found at my blog Kratisto Investing (kratistoinvesting.blogspot.com), or Twitter (@Kratisto_Invest).
Dad to two lovely daughters, full-time rancher, part-time architect, unapologetic patriot and capitalist. More practical to ask forgiveness than permission. The government that governs least, governs best.
Regarding investing: Research first the integrity of your Chiefs and Board. If they pass the smell test, then and only then research the pipeline. Diversification just might be better achieved by investing in one company with many catalysts, than many companies with few. Be patient. Be thankful. Keep the faith.
I have been investing in the stock market as a personal investor for approximately ten years now. I began my training in an accelerated pre-med program, and have continued both my interest and research in related topics. I only invest in companies after very lengthy deliberation, although am apt to leave the market entirely for periods of time. I have almost exclusively traded in the biotech sector.
I am a fund analyst seeking heavily undervalued small cap stocks for long term investment. If the opportunity presents itself I will also play the short side on companies that I feel are heavily overvalued.
Fourth year medical student at a US medical institution pursuing an MD. I invest mostly in biotech stocks on the long and short side through both equity and option positions. I focus mostly on technical analysis, pre/post clinical trial results, FDA advisory committee meetings and drug approval events.
Dale Roberts is an Investment Funds Associate with Tangerine Investment Funds Limited, a subsidiary of Tangerine Bank wholly owned by Scotiabank. My articles are for information purposes only and do not constitute investment advice or an offer or the solicitation of an offer to buy or sell any securities. These articles are my personal opinion and are not those of Tangerine Bank or its subsidiaries. Remember past performance is not guaranteed and may not be repeated. Investment strategies are not suitable for everyone and you should always conduct your own research or speak to a financial advisor.
I am an investor who has a passion for discovering and investing in the compelling and breakthrough companies of our time. I share my humble (and often times not so humble) opinions to help others to ask their own questions as they conduct their own due diligence.
Disclaimer: Articles provide opinions and information, but do not contain recommendations or personal investment advice to any specific person for any particular purpose. Do your own research and/or obtain suitable personal advice from an investment professional.
A swing trader by nature, I stick mainly to the big boards stocks under $5. I consider myself still somewhat of a "growing" trader as I have only been actively trading since 2006. The hardest part to overcome has been learning what kind of trader I can be and sticking to that style. I look for certain traits in a stock that could be holding it back and evaluating the risk for a short swing to long term hold. I enjoy helping others in researching a stock they may be looking into and offering ideas of what they may want to look into further. With over 8,000 stocks to choose from there are plenty of fish out there. My analysis is a very basic overview of fundamentals prompted by my interest of how the technical side looks. My picks and my analysis are of my own research and should not be used as investment advice.
That's what I would like to bring across more than anything. I am not a professional trader/investor. I am not even remotely wealthy. I can not make you rich. I have made some money in short term trading and I have lost some money doing the same. Short term trading has been a wash for me as any profits taken were quickly usurped by idiotic losses.
Why? Because I rushed in to trading in companies that I knew next to nothing about. Maybe I saw a newsletter. Maybe a friend mentioned something. However it happened, in retrospect, it was the wrong reason to invest. It sure felt good when a trade was a winner, but I'd take those profits and either try and chase, or would invest in a stinker immediately afterwards.
Through it all though, I have maintained several stocks that I was long out of the gate on, because I saw potential when I studied the companies. These were companies that I saw as having massive upside with minimal risk. Consequently, I invested more in these longs than I ever risked on the short term plays.
These are the stocks that I would like to write about, as I feel they are worth my time to write about.
Everything I write is, of course, my opinion, and in no way should be taken as investment advice.
I am going to write and I don't care if you read it.
Trader of equities and options for over 12 years. Proprietary trading strategy involving options and biotech with a very high win to loss ratio. SMID cap biotech. Passionate about science and cooking.
"Win or lose, everybody gets what they want out of the market. Some people seem to like to lose, so they win by losing money."
Biomed Group is an independent research group, with a goal of providing investors with real-time information and exclusive specialised research on biotechnology stocks, so that they can make informed investment decisions.